Upfront Management of Patients With Multiple Myeloma

Video
Conference|National Comprehensive Cancer Network Annual Meeting (NCCN)

In this video we discuss the initial symptoms and diagnosis of multiple myeloma as well as upfront treatment with autologous stem cell transplantation and newer agents.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      In this video, George Somlo, MD, of the City of Hope Comprehensive Cancer Center in Duarte, California, discusses the initial symptoms and diagnosis of multiple myeloma as well as upfront treatment with autologous stem cell transplantation and newer agents.

      Dr. Somlo gave a presentation on this topic at the 11th Annual National Comprehensive Cancer Network (NCCN) Hematologic Malignancies Congress, held September 1–October 1 in New York.

      Recent Videos
      More follow-up data will better elucidate the impact of frontline use of hypomethylating agents in patients with myelodysplastic syndromes.
      Bexmarilimab Shows Survival Efficacy in Relapsed/Refractory MDS
      Greater direct access to academic oncologists may help address challenges associated with a lack of CAR T education in the community setting.
      Spreading Greater CAR T-Cell Therapy Education in the Community Setting
      Certain bridging therapies and abundant steroid use may complicate the T-cell collection process during CAR T therapy.
      Avoiding CAR T-Cell Collection Problems Following Bridging Therapies
      Educating community practices on CAR T referral and sequencing treatment strategies may help increase CAR T utilization.
      Academic/Community Collaboration May Help Facilitate CAR T Therapy Access
      A retrospective study sought to assess CRS and ICANS onset and duration, as well as non-relapse mortality causes in patients infused with CAR T-cell therapies.
      Hybrid Model of CAR T-Cell Therapy May Help Manage Treatment-Related Infections
      A retrospective study sought to assess CRS and ICANS onset and duration, as well as non-relapse mortality causes in patients infused with CAR T-cell therapies.
      Secondary Malignancies Risk Still in Question Following CAR T-cell Therapy for Lymphoma
      A retrospective study sought to assess CRS and ICANS onset and duration, as well as non-relapse mortality causes in patients infused with CAR T-cell therapies.
      Study Aims to Address CAR T Accessibility Among Disadvantaged Groups
      Future meetings may address how immunotherapy, bispecific agents, and CAR T-cell therapies can further impact the AML treatment paradigm.
      Addressing Challenges in TP53-Mutant Acute Myeloid Leukemia
      Treatment with revumenib appeared to demonstrate efficacy among patients with KMT2A-rearranged acute leukemia in the phase 2 AUGMENT-101 study.
      Menin Inhibitor Developments Move Acute Myeloid Leukemia Landscape Forward
      Advocacy groups such as Cancer Support Community and the Leukemia & Lymphoma Society may help support patients with CML undergoing treatment.
      Advocate Outlines Resources for Chronic Myeloid Leukemia Population
      Related Content
      Data from the 2025 EHA Congress show developments in novel therapeutic strategies across different multiple myeloma, leukemia, and lymphoma populations.

      EHA 2025: Top 5 Takeaways for Hematologic Malignancy Management

      Russ Conroy
      June 18th 2025
      Article

      Data from the 2025 EHA Congress show developments in novel therapeutic strategies across different multiple myeloma, leukemia, and lymphoma populations.

      An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.

      CAR T and Transplantation Advances Across Hematologic Cancers at ASCO 2025

      Rahul Banerjee, MD, FACP;Taha Al-Juhaishi, MD;Muhammad Salman Faisal, MD
      June 9th 2025
      Podcast

      An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.

      Results of a post hoc analysis found spleen and symptom response rates to be comparable with ESAs or danazol in combination with ruxolitinib for patients with myelofibrosis who have anemia.

      Similar Splenic, Symptom Responses Are Reported With Ruxolitinib Combos in Myelofibrosis With Anemia

      Ariana Pelosci
      June 13th 2025
      Article

      Results of a post hoc analysis found spleen and symptom response rates to be comparable with ESAs or danazol in combination with ruxolitinib for patients with myelofibrosis who have anemia.

      Therapies like betibeglogene autotemcel have been “life-changing” for patients with β-thalassemia, according to Nora M. Gibson, MD, MSCE.

      Reviewing Real-World Use of Beti-Cel in Transfusion-Dependent β-Thalassemia

      Nora M. Gibson, MD, MSCE;Taha Al-Juhaishi, MD
      May 5th 2025
      Podcast

      Therapies such as betibeglogene autotemcel have been “life-changing” for patients with β-thalassemia, according to Nora M. Gibson, MD, MSCE.

      Treatment with cyclosporin/cyclophosphamide following allogeneic stem cell transplant had improved efficacy vs cyclosporin/methotrexate in patients with high-risk hematologic cancers.

      Cyclosporin/Cyclophosphamide Is a Potential New SOC in GVHD Management

      Ariana Pelosci
      June 13th 2025
      Article

      Treatment with cyclosporin/cyclophosphamide following allogeneic stem cell transplant had improved efficacy vs cyclosporin/methotrexate in patients with high-risk hematologic cancers.

      Zanubrutinib tablets were found to have the same efficacy and safety as capsules based on 2 single-dose, open-label randomized phase 1 studies.

      FDA Approves Zanubrutinib Tablets in Multiple Hematologic Indications

      Roman Fabbricatore
      June 12th 2025
      Article

      Zanubrutinib tablets were found to have the same efficacy and safety as capsules based on 2 single-dose, open-label randomized phase 1 studies.